Quick Answer
Virax Biolabs Group Ltd reported R&D Expense of $1.78 million for fiscal year 2025.
Virax Biolabs Group Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.78M | +13.9% |
| 2024 | $1.56M | -28.3% |
| 2023 | $2.18M | +402.4% |
| 2022 | $433.7K | +260.8% |
| 2021 | $120.2K | — |
- Virax Biolabs Group Ltd showed an increase of +13.9% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Virax Biolabs Group Ltd’s r&d expense has grown by 1380.4% (from $120.2 thousand to $1.78 million).
- The most recent figure is from Virax Biolabs Group Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 2, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: